Study of the QOL Evaluation of Trelagliptin in Patients With Type 2 Diabetes Mellitus

Exclusion Criteria

• •1. Participants who are receiving any oral anti-diabetic medication for the treatment of type 2 diabetes at the start of the screening period.
• •2. Participants diagnosed with type 1 diabetes.
• •3. Participants with severe renal impairment or renal failure (e.g., estimated glomerular filtration rate (eGFR) \<30 mL/min/1.73 m\^2 or on dialysis).
• •4. Participants with serious heart disease or cerebrovascular disorder, or serious pancreatic, blood, or other disease.
• •5. Participants with a history of gastrointestinal resection.
• •6. Participant with a proliferative diabetic retinopathy.
• •7. Participant with malignancy.
• •8. Participants with a history of hypersensitivity or allergy to DPP-4 inhibitors.
• •9. Pregnant, lactating or planning pregnancy during the study period.
• •10. Participants who may need to add or discontinue concomitant medication or change the dose during the study period.
• •11. Participants who will require treatment with a prohibited concomitant medication during the study period.
• •12. Participants participating in other clinical studies.
• •13. Participants assessed ineligible in the study by the principal investigator or the investigator.